Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients
Trishula Therapeutics reported positive Phase 1 results for TTX-030, an anti-CD39 antibody, in first-line metastatic pancreatic cancer patients, with strong median overall survival and marked benefit in HLA-DQhigh patients. The trial evaluated TTX-030 in combination with gemcitabine/nab-paclitaxel, with or without budigalimab, showing a 30% objective response rate and 19.1 months median overall survival. The treatment was well-tolerated, leading to the ongoing Phase 2 ELTIVATE study.
Related Clinical Trials
Reference News
Trishula Therapeutics reported positive Phase 1 results for TTX-030, an anti-CD39 antibody, in first-line metastatic pancreatic cancer patients, with strong median overall survival and marked benefit in HLA-DQhigh patients. The trial evaluated TTX-030 in combination with gemcitabine/nab-paclitaxel, with or without budigalimab, showing a 30% objective response rate and 19.1 months median overall survival. The treatment was well-tolerated, leading to the ongoing Phase 2 ELTIVATE study.